NK CELL-ACTIVATING FUSION PROTEIN, NK CELL, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME

WIPO Patent Application WO/2018/186706

A1

The present invention relates to a fusion protein for treating cancer, and uses thereof. The fusion protein for preventing or treating cancer according to the present invention includes: an antibody or fragment thereof that binds to a tumor-associated antigen; a linker; and a fusion polypeptide including a natural killer cell-inducing protein of CXCL16. Accordingly, when coadministered with a natural killer cell, which is an immunocyte therapeutic agent, the fusion protein greatly increases the introduction of the natural killer cell into a cancer expressing a specific antigen, and thus exhibits a remarkable effect in the prevention or treatment of cancer.

KIM SEOK HO (KR)
LEE JAEMIN (KR)
CHO DUCK (KR)

PCT/KR2018/004043

October 11, 2018

April 05, 2018

Click for automatic bibliography generation  

KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY (KR)

C07K16/30; A61K35/17; A61K39/00; C07K16/28; C07K16/32; C12N5/0783; C12N15/11

WO2014043523A1	2014-03-20
WO2016176756A1	2016-11-10

JP2014518632A	2014-08-07
US20100183516A1	2010-07-22
KR101732126B1	2017-05-02
KR20060079180A	2006-07-05
KR20150063145A	2015-06-08

HESS, CHRISTIAN ET AL.: "Evaluation of Antibody-chemokine Fusion Proteins for Tumor-targeting Applications", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 239, no. 7, 2014, pages 842 - 852, XP002783565, Retrieved from the Internet
"Remington: The Science and Practice of Pharmacy", 2005, UNIVERSITY OF THE SCIENCES IN PHILADELPHIA
See also references of EP 3594242A4

AHN, So Young (KR)

View/Download PDF      PDF Help

Previous Patent: COMPOSITION, CONTAINING SIRAITIA GROSVENORII RESIDUE EXTRACT AS ACTIVE INGREDIENT, FOR PREVENTION, A...

Next Patent: RAILWAY CONNECTING MEMBER FOR CONNECTING TRAIN RAILWAYS HAVING DIFFERENT GAUGES AND TRAIN WHEEL ADAP...